Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: genetics – Page 575

Bioquark Inc. and SC21 Biotech to Collaborate on Novel Cellular Therapies for Long Term HIV Control

Orginal press: http://www.prweb.com/releases/2017/02/prweb14062199.htm

Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel biologics for complex regeneration and disease reversion, and SC21 Biotech, (http://www.sc21bio.tech), a biotechnology company focused on translational therapeutic applications of autologous stem cell therapy, have announced a collaboration to focus on novel cellular reprogramming and production approaches for CCR5 Delta32 homozygous cord blood stem cells, for long-term control of HIV via transplantation.

“We are very excited about this collaboration with SC21 Biotech,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular reprogramming tools and SC21 Biotech’s translational cell therapy experience, will make for a transformational opportunity in this area of HIV disease control.”

HIV-1 infection afflicts more than 35 million people worldwide. For individuals who have access to antiretroviral therapy, these drugs can effectively suppress, but not cure, HIV-1 infection. The only documented case for an HIV/AIDS cure was a patient with HIV-1 and acute myeloid leukemia who received allogeneic hematopoietic cell transplantation from a graft that carried the HIV-resistant CCR5-Delta32 homozygous mutation. The patient has remained without any evidence of HIV infection for more than 8 years after discontinuation of antiretroviral drug therapy.

However, identifying immune matched adult CCR5- Delta32 homozygous donors for a given patients is not readily feasible in part because the prevalence is in only about 0.8%–1% of individuals of northern European descent and much less in other ethnic groups, as well as the fact that for such transplants with adult cells there needs to be a very close HLA match between donor and patient.

In contrast, cord blood that is CCR5- Delta32 homozygous provides a major advantage in that much less stringent HLA matching is required between donor and patient. However, a technological method to cost effectively and industrially scale the production of such cells has been missing.

“We look forward to working closely with Bioquark Inc. on this exciting initiative,” said Mr. Paul Collier, Managing Director of SC21 Biotech. “The ability to apply Bioquark’s cellular reprogramming tools in order to produce industrial quantities of such precious cell lines will offer a much greater global penetration of this important therapeutic modality for HIV.”

“Bioquark has spent several years studying the evolutionarily perfected ability of bioactive moieties found in ooplasms to turn back biological time and re-set cellular regulatory state” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This unique initiative is one more step in our broad translation of such natural capabilities to control the progression of human diseases.”

About Bioquark, Inc.

Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.

About SC21 Biotech

SC21 Biotech is a novel a biotechnology company focused on translational therapeutic applications, as well as expedited, experimental access for “no option” patients, to a novel range of regenerative and reparative biomedical products and services, with the goal of reducing human degeneration, suffering, and death.

Zoltan Istvan on transhumanism, politics and why the human body has to go

A new and extensive interview I did at New Atlas, including ideas about my #libertarian California Governor run. Libertarianism has many good ideas, but two core concepts are the non-aggression principle (NAP) and protection of private property rights—both of which I believe can be philosophically applied to the human body (and the body’s inevitable transhuman destiny of overcoming disease and decay with science and technology):

Zoltan Istvan is a transhumanist, journalist, politician, writer and libertarian. He is also running for Governor of California for the Libertarian Party on a platform pushing science and technology to the forefront of political discourse. In recent years, the movement of transhumanism has moved from a niche collection of philosophical ideals and anarcho-punk gestures into a mainstream political movement. Istvan has become the popular face of this movement after running for president in 2016 on a dedicated transhumanist platform.

We caught up with Istvan to chat about how transhumanist ideals can translate into politics, how technology is going to change us as humans and the dangers in not keeping up with new innovations, such as genetic editing.

New Atlas: How does transhumanism intersect with politics?

Istvan: For me you can never make any headway in the universe, or on planet Earth, if you don’t involve politics because so much money for innovation or research and development comes from the government and so many laws about what you can do. Genetic editing, chip implants, can you get a brain implant that makes you smarter than other people? These things are often directed by the government determining whether it’s illegal or not. You can either be thrown in jail or not thrown in jail – so you must have a political footprint, you must have attorneys on the ground, you must have that kind of legal position that can explain things in terms that a government will understand.

Genetically-engineered hens produce birds of a different feather

Rare breeds of chickens could soon come from entirely different types of hens. The University of Edinburgh’s Roslin Institute with help from US biotechnology company Recombinetics used gene editing techniques to create surrogate hens that grow up to produce eggs with all the genetic information of different breeds.

We’ve seen gene editing and transfer techniques used to create better yeast, bigger trees and even glowing pigs, among numerous other examples, but this is believed to be the first gene-edited bird to come out of Europe.

The team used a gene editing tool called TALEN (for transcription activator-like effector nucleases), which is similar to the more widely publicized CRISPR/Cas9, to delete part of a chicken gene called DDX4 that is related to fertility. Hens with this modification did not produce eggs but were healthy in all other ways.

CellAge Campaign: iPhone Reward Raffle Draw

Mantas from CellAge picks a winner for the iPhone Raffle Reward! ►Campaign Link: https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/ ►Subscribe:
►Reddit AMA: https://www.reddit.com/r/Futurology/comments/5hfmsl/cellage_…ells_with/

Our society has never aged more rapidly – one of the most visible symptoms of the changing demographics is the exponential increase in the incidence of age-related diseases, including cancer, cardiovascular diseases and osteoarthritis. Not only does aging have a negative effect on the quality of life among the elderly but it also causes a significant financial strain on both private and public sectors. As the proportion of older people is increasing so is health care spending. According to a WHO analysis, the annual number of new cancer cases is projected to rise to 17 million by 2020, and reach 27 million by 2030. Similar trends are clearly visible in other age-related diseases such as cardiovascular disease. Few effective treatments addressing these challenges are currently available and most of them focus on a single disease rather than adopting a more holistic approach to aging.

Recently a new approach which has the potential of significantly alleviating these problems has been validated by a number of in vivo and in vitro studies. It has been demonstrated that senescent cells (cells which have ceased to replicate due to stress or replicative capacity exhaustion) are linked to many age-related diseases. Furthermore, removing senescent cells from mice has been recently shown to drastically increase mouse healthspan (a period of life free of serious diseases).

Here at CellAge we are working hard to help translate these findings into humans!

CellAge, together with a leading synthetic biology partner, Synpromics, is going to develop synthetic promoters which are specific to senescent cells (SeneSENSE), as promoters that are currently being used to track senescent cells are simply not good enough to be used in therapies. The most prominently used p16 gene promoter has a number of limitations, for example. As our primary mission is to expand the interface between synthetic biology and aging research as well as drive translational research forward, we will offer senescence reporter assay to academics for free. We predict that in the very near future this assay will be also used as a quality control step in the cell therapy manufacturing process to make cell therapies safer!

Continue reading “CellAge Campaign: iPhone Reward Raffle Draw” | >

The Next Pseudoscience Health Craze Is All About Genetics

Husar, a 38-year-old telecom salesman, had spent most of his life eating the sort of Eastern European fare typical of his native Ukraine: lots of meat, potatoes, salt and saturated fats. DNA Lifestyle Coach suggested his body might appreciate a more Mediterranean diet instead.

Recently, Vitaliy Husar received results from a DNA screening that changed his life. It wasn’t a gene that suggested a high likelihood of cancer or a shocking revelation about his family tree. It was his diet. It was all wrong.

DeepMind just published a mind blowing paper: PathNet

Potentially describing how general artificial intelligence will look like.

Since scientists started building and training neural networks, Transfer Learning has been the main bottleneck. Transfer Learning is the ability of an AI to learn from different tasks and apply its pre-learned knowledge to a completely new task. It is implicit that with this precedent knowledge, the AI will perform better and train faster than de novo neural networks on the new task.

DeepMind is on the path of solving this with PathNet. PathNet is a network of neural networks, trained using both stochastic gradient descent and a genetic selection method.

All inherited diseases including cancer ‘could be cured in the next 20 years’

Definitely yes on gene mutations; however, those where the disease has already appeared, or cancer that has occurred before will require another form of eradication/ prevention. And, that is where Quantum Biosystem technology will be effective in eliminating disease.

ALL inherited diseases could be cured within 20 years, a leading British expert claims.

It includes eradicating life-limiting conditions such as cystic fibrosis and Huntington’s disease.

/* */